Amanda Guidon is a Neurology physician affiliated with Harvard University. OpenAlex indexes 89 publications with 3,706 citations (h-index 26); ClinicalTrials.gov lists 2 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
165 Cambridge St
Suite 820
Boston, MA 021142783
Telephone
855-644-6387Provider last certified this registry record 6 Aug 2025.
Clinical trials
- Physical Activity Monitoring in Myasthenia Gravis
Sponsor: Massachusetts General Hospital
- The Adapting Disease Specific Outcome Measures Pilot Trial for Telehealth in Myasthenia Gravis
Sponsor: Yale University
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
6 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- UCB, Inc.Program year20253 payments$18,378openpaymentsdata.cms.gov ↗
- UCB SAProgram year20251 payment
- Amgen Inc.Program year20253 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Nervous system
37.5%Cholinesterase Inhibitor29.7%Pyridostigmine Bromide100%Part D≥33 patientsGabapentinoids7.8%Gabapentin100%Part D<11 patientsCancer & immunology
32.2%Purine Antimetabolite15.6%Azathioprine100%Part D≥17 patientsComplement Inhibitor12.8%Zilbrysq100%Part D<11 patients+ 1 more class in this area
Metabolism & gastrointestinal
30.3%Corticosteroid27.2%Prednisone100%Part D≥30 patientsPotassium supplement3.1%Potassium Chloride100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
1 NIH research award on record, funded 2022–2026 per NIH RePORTER. The latest:
- Wearable Sensor and Digital Technologies for Quantitative Assessment and Remote Monitoring of Symptoms in Myasthenia Gravis
Biosensics, Llc
FY2026$973,917R44NS122672 - Wearable Sensor and Digital Technologies for Quantitative Assessment and Remote Monitoring of Symptoms in Myasthenia Gravis
Biosensics, Llc
FY2025$973,917R44NS122672 - Wearable Sensor and Digital Technologies for Quantitative Assessment and Remote Monitoring of Symptoms in Myasthenia Gravis
Biosensics, Llc
FY2023$40,712R44NS122672
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Consensus disease definitions for ophthalmic immune-related adverse events of immune checkpoint inhibitors
Journal for ImmunoTherapy of Cancer
2025 - Peripheral nervous system immune-related adverse events due to checkpoint inhibition
Nature Reviews Neurology
2024 - Application of digital tools and artificial intelligence in the Myasthenia Gravis Core Examination
Frontiers in Neurology
2024 - Trends and Disparities in the Utilization of Thymectomy for Myasthenia Gravis in the United States
Neurology Clinical Practice
2024
Similar KOLs
Other experts from the same institution or the same specialty.
Benjamin Ebert, MD
Harvard University
Mark Shrime, MD
Harvard University
Thoralf Sundt, MD
Harvard University
Dhaval Kolte, MBBS, PhD
Harvard University
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”